Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Photo of a clinical trial participant lying in a hospital bed covered with a sheet and wearing an oximeter on their index finger.
The year 2024 saw NSCLC reenter Phesi’s ranking of the top five most-studied diseases for the first time since 2021, while COVID-19 dropped out of the ranking for the first time since its entry.
iStock, gorodenkoff

Breast Cancer Tops Most-Studied Diseases List for Fourth Year but Trial Attrition Rate Rises

A third of Phase 2 clinical trials were terminated in 2024, a 50 percent increase from before the pandemic

Phesi

Phesi provides comprehensive clinical development analytical products and services for biopharmaceutical companies around the world. Their integrated offerings cover the entire clinical development process—from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Jan 21, 2025
|3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

Boston, USA. 21st Jan, 2025: Phesi, a global provider of patient-centric data analytics, has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator™ platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year—followed by solid tumors, stroke, prostate cancer, and non-small cell lung cancer (NSCLC) (Table 1).

Figure 1. Top 5 Global Recruiting Trials by Indication 2024.

Figure 1. Top 5 Global Recruiting Trials by Indication 2024.

Phesi

Phesi’s analysis also found that the clinical trial attrition rate remained high throughout 2024. One in three (31 percent) clinical trials were terminated during Phase 2—rising from 29 percent in 2023 and representing a 50 percent increase from an average of 20 percent before the COVID-19 pandemic (Figure 2). This indicates that the industry is increasingly wasting tens of millions of dollars on trials that ultimately fail. 

“There are two main forces driving treatment innovation: the unmet needs of patients and our improved understanding of disease,” commented Gen Li, PhD, MBA, Phesi CEO and founder. “The former is why breast cancer unsurprisingly remains the world’s most-researched disease, since it is the top killer among women with cancer. The latter explains NSCLC’s re-entry into the top 5, since we have seen an increase in the number of biomarker-specific trials in this disease. This focus on precision medicine is positive news for patients—more precise trials are likely to achieve both a higher success rate and improved ROI.”

Figure 2. Rate of Phase 2 Clinical Trial Attrition 2017–2024.

Figure 2. Rate of Phase 2 Clinical Trial Attrition 2017–2024.

Phesi

The year 2024 saw NSCLC reenter Phesi’s ranking of the top five most-studied diseases for the first time since 2021, while COVID-19 dropped out of the ranking for the first time since its entry. The analysis reveals that more than half (51 percent) of all NSCLC trials are now biomarker-specific. The full report from Phesi contains further data exploring the current state of NSCLC clinical development and details the biomarkers that are of most interest to researchers.

Li added, “We are disappointed that the Phase II clinical trial attrition rate remained so high in 2024. We hoped that we would see a reduction in the attrition rate now that the COVID-19 pandemic is behind us. This attrition rate will inevitably have a knock-on effect in Phase III and a significant negative impact on companies’ ROI. It is clearer than ever that sponsors need to focus on utilizing data science, AI and clinical data analytics for precision trials: ensuring every aspect of trial design is optimized, along with identifying the most suitable investigator sites, to deliver smarter trials and faster cures.”

Phesi has produced yearly reports on the world’s most studied diseases since 2021, and has published multiple interim reports exploring various elements of clinical development. The reports are based on data from Phesi’s AI-driven Trial Accelerator platform, the world’s largest contextualized clinical trial database.  

Table 1—Clinical development: Top five most studied diseases  

2021 (75,020 trials)

2022 (80,917 trials) 

2023 (65,749 trials) 

2024 (67,469 trials) 

Breast cancer

Breast cancer 

Breast cancer 

Breast cancer 

COVID-19

COVID-19 

Solid tumor 

Solid tumor 

Non-small cell lung cancer

Prostate cancer 

Stroke 

Stroke 

Solid tumor

Solid tumor 

COVID-19 

Prostate cancer 

Multiple myeloma

Stroke 

Prostate cancer 

Non-small cell lung cancer

All data from Phesi Trial Accelerator ™